SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs upcoming Q3 earnings report is the main focus, with traders watching guidance, subscriber engagement and advertising growth after a steep share-price decline and recent layoffs and content-leadership changes. Views are split between hopes for a rebound if results or outlook exceed subdued expectations and bets on further losses if growth concerns persist.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas rally is tied to enthusiasm for its Merck-partnered personalized melanoma vaccine after positive Phase 3 topline results, with traders focused on the detailed data presentation at ESMO. Bulls see validation of a broader cancer-vaccine platform and momentum, while bears argue expectations and valuation are stretched and warn of a possible sell-the-news reaction.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Traders are citing a reported ClinicalTrials.gov update adding a site to Sareptas ENHANCE Elevidys safety study as a possible trigger for the rebound, though they note the study timeline reportedly slipped. The broader debate centers on whether upcoming DM1 and FSHD data can support a recovery, with some traders pointing to short covering and others stressing that those clinical results remain unproven.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Seas sharp selloff and fresh low are being linked by traders to plans for a potential Monee listing and the launch of Sea Cloud, alongside concerns about spending and competition in e-commerce. Some see a Monee separation as value-unlocking, while others view the plans and uncertainty around them as a reason to sell; claims of further undisclosed bad news remain speculation.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs earnings beat and higher outlook have been met with a sharp selloff, prompting traders to question why strong demand and orders are not lifting the shares. The debate centers on rising costs, weaker cash conversion and an insurance loss, while some investors view the reaction as excessive given the improved guidance.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is drawing attention after its quarterly earnings beat and improved cash-flow outlook failed to prevent a sharp selloff, as traders focused on narrowed full-year profit guidance with no increase to its midpoint. Some see the new buyback and cash generation as support for the shares, while others argue the outlook disappointed despite the strong quarter.

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Myriad Genetics, Inc.

Myriads agreement to sell its prenatal testing business to Labcorp is driving the sharp rally, with traders viewing the cash proceeds as a potential balance-sheet and strategic reset. Others argue the divestiture removes a significant revenue stream and leaves concerns about debt and weakness in the remaining business; the transaction is still pending approval and closing.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

Attention centers on TG Therapeutics MSToronto presentations, especially initial Phase 1 azer-cel data in progressive MS and additional BRIUMVI results, with commercial growth and a future subcutaneous formulation also part of the bullish case. Traders are anticipating a catalyst-driven move, though some caution that the azer-cel results remain uncertain and complain that the shares have struggled to break out of a trading range.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

A sharp COMP rally has sparked breakout talk, with traders pointing to rising momentum, chart patterns, and the tokens limited supply; others remain skeptical, calling it a volatile bounce and questioning whether gains can hold.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

RAP-219s Phase 2 trial in bipolar mania met its primary and secondary endpoints, prompting bullish trading and analyst optimism, including an upgrade. The community is divided over the modest placebo-adjusted benefit and concerns about agitation and discontinuations; the initial surge faded as traders debated whether the data justify further upside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Barrick’s Q4 Earnings Beat Expectations – So, What Is Dragging The Stock Down In Premarket Today?

Equity

Barrick posted a substantial earnings increase in the fourth quarter but expects gold and copper production for 2026 to be slightly lower than 2025 levels.

Why Is Albemarle Stock Up 6% Today?

UBS upgraded Albemarle to ‘Buy’ from ‘Neutral’ with a price target of $185, up from $107. 


VanEck ETF Trust - VanEck Copper and Electrification Metals ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The company expects 2026 gold production to range between 2.90 million and 3.25 million ounces, just below the 3.26 million ounces produced in fiscal 2025.</li><li>Management gets board approval for the IPO of NewCo, a subsidiary that would hold its North American gold assets, the company said.</li><li>Fourth-quarter revenue surged 31% to $6 billion, significantly above analysts’ average of $5.16 billion.</li></ul>Barrick Mining Corp. (B) said on Thursday it expects gold and copper production for 2026 to be slightly lower than full-year 2025 levels, on the back of a significant increase in fourth-quarter earnings.The company expects 2026 gold production to range between 2.90 million and 3.25 million ounces, just below the 3.26 million ounces produced in fiscal 2025. That figure marked a 17% year-over-year decline but still met the company’s guidance.Copper output is forecast at 190,000 to 220,000 tonnes for 2026. In 2025, copper production climbed 13% from 2024 to 220,000 tonnes, also in line with the company’s expectations.<h2 class="st-heading-2">Better-Than-Expected Q4 Earnings</h2>Barrick delivered better-than-expected fourth-quarter (Q4) results, with net earnings of $2.41 billion, or $1.43 per share, and adjusted net earnings of $1.75 billion, or $1.04 per share. Analysts on average expected adjusted earnings of $0.87 per share, according to Koyfin data. Revenue surged 31% to $6 billion, significantly above analysts’ average of $5.16 billion. The board also approved a quarterly dividend of $0.42 per share.As of Dec. 31, 2025, Barrick reported proven and probable gold reserves of 85 million ounces at an average grade of 0.98 g/t, down from 89 million ounces in 2024.<h2 class="st-heading-2">NewCo IPO Update</h2>Barrick said that management has received approval to move forward with plans for an initial public offering (IPO) of NewCo, a subsidiary that would hold its North American gold assets. It stated that the completion is targeted for late 2026.NewCo will include stakes in Nevada Gold Mines, Pueblo Viejo, and the wholly owned Fourmile discovery in Nevada. Barrick first announced the IPO plans in December last year.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the upbeat fourth-quarter earnings, <a href="https://stocktwits.com/symbol/B">B stock</a> was down over 2% in pre-market trading on Thursday. Peers Newmont Corp. (NEM) and Anglogold Ashanti (AU) were trading nearly 3% lower as spot gold (XAU/USD) prices sank 2.5% to $4,840 an ounce at the time of writing.Retail sentiment on Stocktwits changed to ‘neutral’ from ‘bearish’ a day earlier, amid ‘high’ message volumes.One user expects the declining gold prices to overshadow the robust earnings.<stembedurl>https://stocktwits.com/Guydude1422/message/644075079</stembedurl>Another user raised questions on shareholding related to NewCo’s IPO.<stembedurl>https://stocktwits.com/eyedoc00/message/644071795</stembedurl>Barrick’s shares have gained around 7% so far in 2026.Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/jp-morgan-gold-bitcoin-forecast/cZbZewsR4Vm">JPMorgan Says Bitcoin Now Has A Better Long-Term Appeal Relative To Gold – BTC Declines Below $70,000</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Barrick Mining Corporation.

Barrick Mining Corp

SPDR Gold Shares ETF

VanEck Green Metals ETF

BlackRock Institutional Trust Company N.A. - iShares MSCI Global Metals & Mining Producers ETF

VanEck Rare Earth and Strategic Metals ETF

SPDR Metals & Mining ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$38.85
Prev Close	$38.69
Open	$38.00
Dividend Yield	N/A
50-Day Moving Average	$42.93
Beta	N/A
Avg. Volume	3,864.84
PE Ratio	N/A

52-Week High	$49.42
52-Week Low	$29.27
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

GMET Fundamentals